CY1115212T1 - Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44 - Google Patents
Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44Info
- Publication number
- CY1115212T1 CY1115212T1 CY20141100072T CY141100072T CY1115212T1 CY 1115212 T1 CY1115212 T1 CY 1115212T1 CY 20141100072 T CY20141100072 T CY 20141100072T CY 141100072 T CY141100072 T CY 141100072T CY 1115212 T1 CY1115212 T1 CY 1115212T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cytotoxicity
- expression
- mediation
- cells presenting
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
Abstract
Αυτή n εφεύρεση αναφέρεται στην διάγνωση και αγωγή καρκινικών νόσων, ειδικά στην διαμεσολάβηση στην κυτταροτοξικότητα κυττάρων όγκου που παρουσιάζουν έκφραση στην επιφάνεια τους της CD44 και ειδικότερα στην χρήση αντισωμάτων τροποποιητικών του καρκίνου (CDMAB), προαιρετικά σε συνδυασμό με έναν ή περισσότερους χημειοθεραπευτικούς παράγοντες, σαν ένα μέσο για την έναρξη της κυτταροτοξικής απόκρισης. Η εφεύρεση ακόμα αναφέρεται σε δοκιμασίες πρόσδεσης οι οποίες χρησιμοποιούν τα CDMAB της παρούσας εφεύρεσης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/364,013 US7947496B2 (en) | 1999-10-08 | 2006-02-28 | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
EP07701821.6A EP1989233B1 (en) | 2006-02-28 | 2007-02-23 | Cytotoxicity mediation of cells evidencing surface expression of cd44 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115212T1 true CY1115212T1 (el) | 2017-01-04 |
Family
ID=38458603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100072T CY1115212T1 (el) | 2006-02-28 | 2014-01-29 | Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44 |
Country Status (16)
Country | Link |
---|---|
US (3) | US7947496B2 (el) |
EP (2) | EP2508536A1 (el) |
JP (2) | JP5247474B2 (el) |
CN (2) | CN101432307B (el) |
AU (1) | AU2007219656B2 (el) |
CA (1) | CA2643708A1 (el) |
CY (1) | CY1115212T1 (el) |
DK (1) | DK1989233T3 (el) |
ES (1) | ES2444408T3 (el) |
HK (1) | HK1120527A1 (el) |
NZ (1) | NZ570776A (el) |
PL (1) | PL1989233T3 (el) |
PT (1) | PT1989233E (el) |
SI (1) | SI1989233T1 (el) |
TW (1) | TW200731987A (el) |
WO (1) | WO2007098575A1 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090004103A1 (en) * | 1999-10-08 | 2009-01-01 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7419792B2 (en) * | 1999-10-08 | 2008-09-02 | Arius Research Inc. | Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody |
US7947496B2 (en) * | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20080124327A1 (en) * | 1999-10-08 | 2008-05-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
CN101663049A (zh) * | 2007-03-09 | 2010-03-03 | 霍夫曼-拉罗奇有限公司 | 证明cd44表面表达的细胞的细胞毒性介导 |
EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
US8853149B2 (en) | 2010-03-19 | 2014-10-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Integrin interaction inhibitors for the treatment of cancer |
WO2012129335A2 (en) * | 2011-03-21 | 2012-09-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc | Hyd1 peptides for relapsed cancer |
US10018630B2 (en) | 2011-09-07 | 2018-07-10 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell isolation |
WO2015048477A1 (en) | 2013-09-27 | 2015-04-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
CN109402064B (zh) * | 2018-11-05 | 2021-05-14 | 湖南省肿瘤医院 | 杂交瘤细胞株及其产生的单克隆抗体和应用 |
CN112569351B (zh) * | 2020-12-16 | 2021-10-15 | 南通大学 | Cd44抗体在制备治疗帕金森疾病的药物中的应用 |
CN114250200A (zh) * | 2021-12-23 | 2022-03-29 | 蚌埠医学院 | 一种非小细胞肺癌脑转移和脊髓转移的动物模型构建方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US486158A (en) | 1892-11-15 | John cook | ||
US4172124A (en) * | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4828991A (en) * | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
NZ222509A (en) * | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
US4861581A (en) * | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5171665A (en) * | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US5980896A (en) * | 1989-06-30 | 1999-11-09 | Bristol-Myers Squibb Company | Antibodies reactive with human carcinomas |
DE4014510A1 (de) * | 1990-05-07 | 1991-11-14 | Kernforschungsz Karlsruhe | Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
DE69229254T2 (de) * | 1991-10-30 | 1999-09-23 | Idemitsu Kosan Co | Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
IL105008A0 (en) * | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
EP0672130A1 (en) | 1992-11-20 | 1995-09-20 | Isis Innovation Limited | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
US5879898A (en) * | 1992-11-20 | 1999-03-09 | Isis Innovation Limited | Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors |
DE69432926T2 (de) * | 1993-02-05 | 2004-05-13 | Epigen, Inc., Wellesley | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
US5693322A (en) * | 1993-03-11 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Enhanced intercellular interaction by associational antibody molecules |
DE69406664T2 (de) | 1993-06-18 | 1998-06-04 | Biotie Therapies Oy | Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6 |
ATE243745T1 (de) | 1994-01-31 | 2003-07-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
WO1996000084A1 (en) * | 1994-06-24 | 1996-01-04 | Torchilin Vladimir P | Use of autoantibodies for tumor therapy and prophylaxis |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
AU6721696A (en) * | 1996-07-15 | 1998-03-06 | Human Genome Sciences, Inc. | Cd44-like protein |
EP0826696B1 (de) * | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
DE19653607A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Int | Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen |
DE19708713C2 (de) * | 1997-03-04 | 2002-11-28 | Boehringer Ingelheim Int | Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen |
US5816468A (en) * | 1997-06-24 | 1998-10-06 | Testo Industries Corp. | No-idle-striking structure for nailing machines |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
US6657048B2 (en) * | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US6180357B1 (en) * | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
US20040001789A1 (en) * | 1999-10-08 | 2004-01-01 | Young David S. F. | Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof |
US7252821B2 (en) * | 1999-10-08 | 2007-08-07 | Arius Research Inc. | Cancerous disease modifying antibodies |
US7189397B2 (en) | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
WO2002082076A2 (en) | 2001-04-03 | 2002-10-17 | Merck Patent Gmbh | Renal cell carcinoma tumor markers |
US20030103985A1 (en) * | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
CN1541226A (zh) | 2001-05-18 | 2004-10-27 | ���ָ��Ӣ��ķ�������Ϲ�˾ | CD44v6特异性的抗体 |
JP2005518393A (ja) | 2001-12-21 | 2005-06-23 | アリアス リサーチ、インコーポレイテッド | 個別化抗癌抗体 |
US7399835B2 (en) * | 2004-02-26 | 2008-07-15 | Arius Research Inc. | Cancerous disease modifying antibodies |
US7319674B2 (en) | 2003-07-24 | 2008-01-15 | Cisco Technology, Inc. | System and method for exchanging awareness information in a network environment |
US7348413B2 (en) * | 2004-02-26 | 2008-03-25 | Arius Research Inc. | Cancerous disease modifying antibodies |
-
2006
- 2006-02-28 US US11/364,013 patent/US7947496B2/en not_active Expired - Fee Related
- 2006-05-18 TW TW095117643A patent/TW200731987A/zh unknown
-
2007
- 2007-02-23 JP JP2008556619A patent/JP5247474B2/ja not_active Expired - Fee Related
- 2007-02-23 WO PCT/CA2007/000281 patent/WO2007098575A1/en active Application Filing
- 2007-02-23 CA CA002643708A patent/CA2643708A1/en not_active Abandoned
- 2007-02-23 CN CN2007800154239A patent/CN101432307B/zh not_active Expired - Fee Related
- 2007-02-23 SI SI200731391T patent/SI1989233T1/sl unknown
- 2007-02-23 NZ NZ570776A patent/NZ570776A/en not_active IP Right Cessation
- 2007-02-23 CN CN2013100529947A patent/CN103197067A/zh active Pending
- 2007-02-23 AU AU2007219656A patent/AU2007219656B2/en not_active Ceased
- 2007-02-23 EP EP12174631A patent/EP2508536A1/en not_active Withdrawn
- 2007-02-23 ES ES07701821.6T patent/ES2444408T3/es active Active
- 2007-02-23 PL PL07701821T patent/PL1989233T3/pl unknown
- 2007-02-23 DK DK07701821.6T patent/DK1989233T3/da active
- 2007-02-23 PT PT77018216T patent/PT1989233E/pt unknown
- 2007-02-23 EP EP07701821.6A patent/EP1989233B1/en not_active Not-in-force
-
2008
- 2008-07-01 US US12/217,279 patent/US8017117B2/en not_active Expired - Fee Related
-
2009
- 2009-01-20 HK HK09100600.3A patent/HK1120527A1/xx not_active IP Right Cessation
-
2011
- 2011-08-15 US US13/210,183 patent/US20120107233A1/en not_active Abandoned
-
2013
- 2013-02-18 JP JP2013029374A patent/JP2013165710A/ja active Pending
-
2014
- 2014-01-29 CY CY20141100072T patent/CY1115212T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN101432307B (zh) | 2013-06-12 |
US8017117B2 (en) | 2011-09-13 |
HK1120527A1 (en) | 2009-04-03 |
CA2643708A1 (en) | 2007-09-07 |
AU2007219656B2 (en) | 2013-02-07 |
EP2508536A1 (en) | 2012-10-10 |
PL1989233T3 (pl) | 2014-04-30 |
TW200731987A (en) | 2007-09-01 |
US20120107233A1 (en) | 2012-05-03 |
EP1989233B1 (en) | 2013-11-06 |
US20060216233A1 (en) | 2006-09-28 |
CN103197067A (zh) | 2013-07-10 |
JP2009529497A (ja) | 2009-08-20 |
US20080274049A1 (en) | 2008-11-06 |
SI1989233T1 (sl) | 2014-02-28 |
CN101432307A (zh) | 2009-05-13 |
PT1989233E (pt) | 2014-02-11 |
US7947496B2 (en) | 2011-05-24 |
JP2013165710A (ja) | 2013-08-29 |
WO2007098575A1 (en) | 2007-09-07 |
EP1989233A1 (en) | 2008-11-12 |
ES2444408T3 (es) | 2014-02-24 |
JP5247474B2 (ja) | 2013-07-24 |
DK1989233T3 (da) | 2014-01-13 |
NZ570776A (en) | 2011-03-31 |
EP1989233A4 (en) | 2010-05-05 |
AU2007219656A1 (en) | 2007-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115212T1 (el) | Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44 | |
ATE500844T1 (de) | Detektion der mcsp-oberflächenexpression einer zelle | |
HK1175846A1 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd44 cd44 | |
CY1118880T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
CY1122155T1 (el) | Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης | |
CY1117476T1 (el) | Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
ATE492651T1 (de) | Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs | |
MA32190B1 (fr) | Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation | |
AR048006A1 (es) | CONJUGADOS DE ALMIDON DE HIDROXIALQUILO Y UNA PROTEíNA | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
TW200637875A (en) | Cytotoxicity mediation of cells evidencing surface expression of CD63 | |
WO2007095729A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of cd63 | |
ATE497976T1 (de) | Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren | |
CY1120436T1 (el) | Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου | |
ATE473279T1 (de) | In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 | |
DOP2009000208A (es) | Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana | |
CR11238A (es) | Mediacion de citotoxicidad de celulas que evidencian la expresion superficial de cd9 | |
CY1113022T1 (el) | Ακτινoφαρμακευτικες συνθεσεις οι οποιες περιεχουν πολυσακχαριτες εμβολιασμενους με πολυαμιδια | |
GT200600108A (es) | Control de plagas | |
PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso | |
MX2009001014A (es) | Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie. | |
DE602006010187D1 (de) | Einzelsequenzhybridisierungssonden | |
ATE525401T1 (de) | Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene |